Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03394365 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

A Phase 3 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders, sponsored by Pierre Fabre Medicament.

Recruiting
Registry status
Phase 3
Development phase
115
Enrollment target
20
Study locations

NCT03394365: Recruiting Phase 3 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders, sponsored by Pierre Fabre Medicament.

NCT03394365 is a Phase 3 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders that is actively recruiting participants, run by Pierre Fabre Medicament. The registered enrollment target is 115 participants, below the 178-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03394365, a Phase 3 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders, is actively recruiting participants, sponsored by Pierre Fabre Medicament.

RECRUITING
Registry status
Phase 3
Development phase
115 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Conditions Studied

Stem Cell Transplant Complications Lymphoproliferative Disorders Solid Organ Transplant Complications Allogeneic Hematopoietic Cell Transplant Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

Interventions

  • BIOLOGICAL tabelecleucel

Study Locations (20)

California

  • City of Hope (Adults and Pediatrics) - Duarte
  • University of California San Diego Moores Cancer Center (Adults only) - La Jolla
  • Loma Linda University Medical Center (Adults only) - Loma Linda
  • Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) - Los Angeles
  • UCLA Medical Center (Adults and Pediatrics) - Los Angeles
  • University of California Davis Comprehensive Cancer Center (Adults only) - Sacramento

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics) - Chicago
  • University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only) - Chicago
  • Loyola University Medical Center (Adults and Pediatrics) - Maywood

Florida

  • University of Florida (Adults and Pediatrics) - Gainesville
  • University of Miami/Jackson Memorial Hospital (Adults only) - Miami

Georgia

  • Winship Cancer Institute (Adults only) - Atlanta
  • Arthur M. Blank Hospital (Pediatrics) - Atlanta

New York

  • Weill Cornell Medicine (Adults only) - New York
  • Columbia University Medical Center (Adults and Pediatrics) - New York

Connecticut

  • Yale University (Adults and Pediatrics) - New Haven

District of Columbia

  • MedStar Georgetown University Hospital (Adults and Pediatrics) - Washington D.C.

Maryland

  • University of Maryland School of Medicine (Adults only) - Baltimore

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2017-12-29
Est. Completion 2030-08
Phase Phase 3
Pierre Fabre Medicament

8 total trials

What NCT03394365 shows while recruiting

NCT03394365 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (35% lower).

The record links to 5 conditions, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 1 intervention - of which tabelecleucel is the first listed.

NCT03394365 names 20 study sites across 10 states, led by California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT03394365 about?

NCT03394365 is a clinical study titled "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy". The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab...

What is the current status of trial NCT03394365?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2017-12-29. Estimated completion is 2030-08.

What conditions does trial NCT03394365 study?

This clinical trial studies the following conditions: Stem Cell Transplant Complications, Lymphoproliferative Disorders, Solid Organ Transplant Complications, Allogeneic Hematopoietic Cell Transplant, Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD).

What interventions are being tested in trial NCT03394365?

The interventions under investigation include: tabelecleucel (BIOLOGICAL).

Who is sponsoring clinical trial NCT03394365?

This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03394365 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stem Cell Transplant Complications

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03394365's enrollment target sits among peer trials

115 7th of 15 higher than 9 of 15 other Stem Cell Transplant Complications trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stem Cell Transplant Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02346929 · 115 participants · NA

    Hematoma Block for Distal Radius Fracture

  • NCT03907475 · 115 participants · Phase 2

    Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

  • NCT05086692 · 115 participants · Phase 1

    A Beta-only IL-2 ImmunoTherapY Study

  • NCT05167786 · 115 participants · NA

    Locomotor Function Following Transcutaneous Electrical Spinal Cord Stimulation in Individuals With Hemiplegic Stroke

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03394365

Source: ClinicalTrials.gov NCT03394365, the US trial registry maintained by the National Library of Medicine. NCT03394365 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.